Priscilla Sugianto
Investor at Vivo Capital
San Francisco, California
Overview
Work Experience
Principal
2020 - Current
Vivo Capital is a $8B AUM healthcare-focused investment firm. We are currently investing out of 3 vehicles: our flagship fund IX (late-stage VC, growth, PE) of $1.6B, Innovation Fund II (VC) of ~$330M, and opportunity fund (long-only public vehicle) of $~700M.
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Board Member
2023
Board Member
2022
Inspirna is a biotechnology company developing drugs for the treatment of cancer.
Raised $144,596,738.00 from The New York City Investment Fund, Sixty Degree Capital, Sofinnova Partners, Dreavent 6, Novo Holdings, Sands Capital Ventures, Vivo Capital and Lepu Medical.
Board Member
2024
Board Observer
2022
Bonum Therapeutics creates a technology platform to treat a wide range of diseases.
Raised $93,000,000.00 from Roche Venture Fund, Digitalis Ventures, RiverVest, Vivo Capital, Codon Capital and 3×5 Partners.
Assistant Vice President
2017 - 2020
CBC Group (fka C-Bridge Capital) is a healthcare-dedicated private equity firm with $4.7B of AUM focused on platform-building and buyout investment opportunities across three core areas: biopharma, medtech, and healthcare services. Its flagship strategy features an operationally intensive approach. Its representative investment, includes: I-Mab Biopharma (NASDAQ: IMAB), Everest Medicines (HKEX:1952.HK), among others. CBC also manages a complementary private credit strategy (Royalty Bridge Fund/RBF) dedicated to provide alternative non-dilutive financing to healthcare companies backed by royalties, revenue interest, and other cash flows generated by the sale of healthcare products and services. I was involved in the fund creation, strategy, fundraising, and initial capital deployment. Deals and boards involvement includes (but not limited to): - Everest Medicines (HKEX:1952.HK)- company creation/Series A and Series B. Board observer - AffaMed Therapeutics (Private)- company creation/ JV turned to licensing agreement with Samsung Bioepis/Series A and merger with EverInsight. Board observer - Graybug Vision (NASDAQ: GRAY)- $80M crossover. Boad observer - Paratek (NASDAQ: PRTK)- $60M royalty/credit deal
Business and Corporate Development
2017 - 2020
Part of the founding investor (incubated by CBC group) and team member. Involved in various roles and phases of the company start-up. Worked closely with C-suite (CEO, CFO, CBO, President, etc) and board directors in business development (involved in Immunomedics Trodelvy deal among others), strategy, and financing (series A to crossover to IPO). Everest (1952.HK) was listed in HKEX in 2020 at US$2.7B valuation, just under 3 years since inception in 2017. Prior to the listing, Everest had raised money in private market from top tier investors including: RA Capital, Hillhouse Capital, Decheng Capital, Cormorant, Janus Henderson, Rock Springs Capital, and HBM, to name a few.
Venture Capital- Health Tech/Services
2016 - 2017
Flare Capital is a team of proven healthcare technology venture capital investors who raised one of the industry’s largest dedicated venture capital funds focused exclusively on early stage and emerging growth investments in healthcare technology innovation. https://www.flarecapital.com/our-team
Flare Capital Partners provides capital for early-stage and emerging healthcare technology companies.